Effects of NSAIDs on differentiation and function of human and murine osteoclasts - Crucial 'Human Osteoclastology'

Pharmaceuticals

Volumn 3, Issue 5, 2010, Pages 1394-1410

  Kotake, Shigeru ^a   Yago, Toru ^a   Kawamoto, Manabu ^a   Nanke, Yuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Interleukin 17 (IL 17); Non steroidal anti inflammatory drugs (NSAIDs); Osteoclast; Osteoclastogenesis; Osteoclastology; Prostaglandin E2 (PGE2)

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLURBIPROFEN 4 NITROXYBUTYL ESTER; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; TEPRENONE; TUMOR NECROSIS FACTOR ALPHA;

ARTHROPATHY; BONE METABOLISM; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MOUSE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM;

EID: 77954889038     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3051394     Document Type: Review

References (67)

1. Kong, Y.Y.; Feige, U.; Sarosi, I.; Bolon, B.; Tafuri, A.; Morony, S.; Capparelli, C.; Li, J.; Elliott, R.; McCabe, S.; Wong, T.; Campagnuolo, G.; Moran, E.; Bogoch, E.R.; Van, G.; Nguyen, L.T.; Ohashi, P.S.; Lacey, D.L.; Fish, E.; Boyle, W.J.; &Penninger, J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402, 304-309.
2. Horwood, N.J; Kartsogiannis, V.; Quinn, J.M.;Romas, E.; Martin, T.J.; Gillespie, M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 1999, 265, 144-150.
3. Kotake, S.; Udagawa, N.; Hakoda, M.; Mogi, M.; Yano, K.; Tsuda, E.; Takahashi, K.; Furuya, T.; Ishiyama, S.; Kim, K.J.; Saito, S.; Nishikawa, T.; Takahashi, N.; Togari, A.; Tomatsu, T.; Suda, T.; Kamatani, N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001, 44, 1003-1012.
4. Kotake, S.; Udagawa, N., Takahashi, N.; Matsuzaki, K.; Itoh, K.; Ishiyama, S.; Saito, S.; Inoue, K.; Kamatani, N.; Gillespie, M.T.; Martin, T.J;Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 1999, 103, 1345-1352.
5. Kotake, S.; Nanke, Y.; Yago, T.; Kawamoto, M.; Yamanaka, H. Human osteoclastogenic T cells and human osteoclastology (Editorial). Arthritis. Rheum. 2009, 60, 3158-3163.
6. Take, I.; Kobayashi, Y.; Yamamoto, Y.; Tsuboi, H.; Ochi, T.; Uematsu, S.; Okafuji, N.; Kurihara, S.; Udagawa, N.; Takahashi, N. Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 2005, 146, 5204-5214.
7. Kotake, S.; Nanke, Y.; Mogi, M.; Kawamoto, M.; Furuya, T.; Yago, T.; Kobashigawa, T.; Togari, A.; Kamatani, N. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur. J. Immunol. 2005, 35, 3353-3363.
8. Luxenburg, C.; Geblinger, D.; Klein, E.; Anderson, K.; Hanein, D.; Geiger, B.; Addadi, L. The architecture of the adhesive apparatus of cultured osteoclasts: From podosome formation to sealing zone assembly. PLoS ONE 2007, 2, e179.
9. Fuller, K.; Kirstein, B.; Chambers, T.J. Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin. Sci. (Lond). 2007, 112, 567-575.
10. Shimizu, S.; Shiozawa, S.; Shiozawa, K.; Imura, S.; Fujita, T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum. 1985, 28, 25-31.
11. Kotake, S.; Sato, K.; Kim, K.J.; Takahashi, N.; Udagawa, N.; Nakamura, I.; Yamaguchi, A.; Kishimoto, T.; Suda, T.; Kashiwazaki, S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 1996, 11, 88-95.
12. Kotake, S.; Higaki, M.; Sato, K.; Himeno, S.; Morita, H.; Kim, K.J.; Nara, N.; Miyasaka, N.; Nishioka, K.; Kashiwazaki, S. Detection of myeloid precursors (granulocyte/macrophage colony forming units) in the bone marrow adjacent to rheumatoid arthritis joints. J. Rheumatol. 1992, 19, 1511-1516.
13. Kotake, S.; Schumacher, H.R. Jr; Yarboro, C.H.; Arayssi, T.K.; Pando, J.A.; Kanik, K.S.; Gourley, M.F.; Klippel, J.H.; Wilder, R.L. In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc. Assoc. Am. Physicians 1997, 109, 286-301.
14. Kotake, S.; Schumacher, H.R. Jr.; Arayssi, T.K.; Gerard, H.C.; Branigan, P.J.; Hudson, A.P.; Yarboro, C.H.; Klippel, J.H.; Wilder, R.L. Gamma interferon and interleukin-10 gene expression in synovial tissues from patients with early stages of Chlamydia-associated arthritis and undifferentiated oligoarthritis and from healthy volunteers. Infect. Immun. 1999, 67, 2682-2686.
15. Kotake, S.; Schumacher, H.R., Jr.; Wilder, R.L. A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples. J. Immunol. Methods 1996, 199, 193-203.
16. Takahashi, N.; Akatsu, T.; Udagawa, N.; Sasaki, T.; Yamaguchi, A.; Moseley, J.M.; Martin, T.J.; Suda, T. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988, 123, 2600-2602.
17. Udagawa, N.; Takahashi, N.; Akatsu, T.; Tanaka, H.; Sasaki, T.; Nishihara, T.; Koga, T.; Martin, T.J.; Suda, T. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrowderived stromal cells. Proc. Natl. Acad. Sci. USA 1990, 87, 7260-7264.
18. Suda, T.; Udagawa, N.; Nakamura, I.; Miyaura, C.; Takahashi, N. Modulation of osteoclast differentiation by local factors. Bone 1995, 17(2 Suppl.1), 87S-91S.
19. Udagawa, N.; Kotake, S.; Kamatani, N.; Takahashi, N.; Suda, T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis. Res. 2002, 4, 281-289.
20. Lam, J.; Nelson, C.A.; Ross, F.P.; Teitelbaum, S.L.; Fremont, D.H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 2001,108, 971-979.
21. Kotake, S.; Nanke, Y.; Kawamoto, M.; Yago, T.; Udagawa, N.; Ichikawa, N.; Kobashigawa, T.; Saito, S.; Momohara, S.; Kamatani, N.; Yamanaka, H. T-cell leukemia translocation-associated gene (TCTA) protein is required for human osteoclastogenesis. Bone 2009, 45, 627-639.
22. Baecher-Allan, C.; Brown, J.A.; Freeman, G.J.; Hafler, D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 2001, 167, 1245-1253.
23. Nanke, Y.; Kotake, S.; Goto, M.; Ujihara, H.; Matsubara, M.; Kamatani, N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack: a possible predictive marker of ocular attack. Mod. Rheumatol. 2008, 18, 354-358.
24. Testa, N.G.; Allen, T.D.; Lajtha, L.G.; Onions, D.; Jarret, O. Generation of osteoclasts in vitro. J. Cell. Sci. 1981, 47, 127-137.
25. Ibbotson, K.J.; Roodman, G.D.; McManus, L.M.; Mundy, G.R. Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells. J. Cell. Biol. 1984, 471-480.
26. Takahashi, N.; Yamana, H.; Yoshiki, S.; Roodman, G.D.; Mundy, G.R.; Jones, S.J.; Boyde, A.; Suda, T. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988, 122, 1373-1382.
27. Hattersley, G.; Chambers, T.J. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology 1989, 125, 1606-1612.
28. Sato, K.; Fujii, Y.; Kasono, K.; Saji, M.; Tsushima, T.; Shizume, K. Stimulation of prostaglandin bone resorption by recombinant human interleukin 1 in fetal mouse bone. Biochem. Biophys. Res. Commun. 1986,138, 618-624.
29. Liu, X.H.; Kirschenbaum, A.; Yao, S.; Levine, A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system. Endocrinology 2005, 146, 1991-1998.
30. Wani, M.R.; Fuller, K.; Kim, N.S.; Choi, Y.; Chambers, T. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999, 140, 1927-1935.
31. Kobayashi, Y.; Mizoguchi, T.; Take, I.; Kurihara, S.; Udagawa, N.; Takahashi, N. Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J. Biol. Chem. 2005, 280, 11395-11403.
32. Han, S.Y.; Lee, N.K.; Kim, K.H.; Jang, I.W.; Yim, M.; Kim, J.H.; Lee, W.J.; Lee, S.Y. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKLinduced osteoclastogenesis. Blood 2005, 106, 1240-1245.
33. Ono, K.; Kaneko, H.; Choudhary, S.; Pilbeam, C.C.; Lorenzo, J.A.; Akatsu, T.; Kugai, N.; Raisz, L.G. Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J. Bone. Miner. Res. 2005, 20, 23-29.
34. Leonhardt, A.; Timmermanns, G.; Roth, B.; Seyberth, H.W. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J. Pediatr. 1992, 120, 546-554.
35. Neale, S.D.; Fujikawa, Y.; Sabokbar, A.; Gundle, R.; Murray, D.W.; Graves, S.E.; Howie, D.W.; Athanasou, N.A. Human bone-derived cells support formation of human osteoclasts from arthroplasty-derived cells in vitro. J. Bone. Joint. Surg. Br. 2000, 82, 892-900.
36. Tsukii, K.; Shima, N.; Mochizuki, S.; Yamaguchi, K.; Kinosaki, M.; Yano, K.; Shibata, O.; Udagawa, N.; Yasuda, H.; Suda, T.; Higashio, K. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 1998, 246, 337-341.
37. Nagai, M.; Sato, N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun. 1999, 257, 719-723.
38. Lader, C.S.; Flanagan, A.M. Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998, 139, 3157-3164.
39. Itonaga, I.; Sabokbar, A.; Neale, S.D.; Athanasou, N.A. 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. Biochem. Biophys. Res. Commun. 1999, 264, 590-595.
40. Kwan Tat, S.; Pelletier, J.P.; Lajeunesse, D.; Fahmi, H.; Duval, N.; Martel-Pelletier, J. Differential modulation of RANKL isoforms by human osteoarthriticsubchondral bone osteoblasts: Influence of osteotropic factors. Bone 2008, 43, 284-291.
41. Stamp, L.K.; James, M.J.; Cleland, L.G. Paracrineupregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: role of interleukin 17 and interferon-gamma. J. Rheumatol. 2004, 31, 1255-1264.
42. Stamp, L.K.; Cleland, L.G.; James, M.J. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J. Rheumatol. 2004, 31, 1246-1254.
43. Yago, T.; Nanke, Y.; Ichikawa, N.; Kobashigawa, T.; Mogi, M.; Kamatani, N.; Kotake, S. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: A novel mechanism of osteoclastogenesis by IL- 17. J. Cell. Biochem. 2009, 108, 947-955.
44. Lam, J.; Takeshita, S.; Barker, J.E.; Kanagawa, O.; Ross, F.P.; Teitelbaum, S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000, 106, 1481-1488.
45. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J. Cell. Biochem. 2001, 83, 70-83.
46. Miranda-Carus, ME.; Benito-Miguel, M.; Balsa, A.; Cobo-Ibanez, T.; Perez de Ayala, C.; Pascual-Salcedo, D.; Martín-Mola, E. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis. Rheum. 2006, 54, 1151-1164.
47. Raza, K.; Falciani, F.; Curnow, S.J.; Ross, E.J.; Lee, C.Y.; Akbar, A.N.; Lord, J.M.; Gordon, C.; Buckley, C.D.; Salmon, M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis. Res. Ther. 2005, 7, R784-R795.
48. Kokkonen, H.; Söderström, I.; Rocklöv, J.; Hallmans, G.; Lejon, K.; RantapääDahlqvist, S. Upregulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis. Rheum. 2010, 62, 383-391.
49. Genovese, M.; Van den Bosch, F.; Roberson, S.; Bojin, S.; Biagini, I.; Ryan, P.; Sloan-Lancaster, J. LY2439821, a Humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis. Rheum. 2010, [Epub ahead of print].
50. Yago, T.; Nanke, Y.; Kawamoto, M.; Furuya, T.; Kobashigawa, T.; Kamatani, N.; Kotake, S. IL- 23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis. Res. Ther. 2007, 9, R96.
51. Chambers, T.J.; Fuller, K.; Athanasou, N.A. The effect of prostaglandins I2, E1, E2 and dibutyryl cyclic AMP on the cytoplasmic spreading of rat osteoclasts. Br. J. Exp. Pathol. 1984, 65, 557-566.
52. Fuller, K.; Chambers, T.J. Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts. J. Bone. Mines. Res. 1989, 4, 209-215.
53. Sarrazin, P.; Hackett, J.A.; Fortier, I.; Gallant, M.A.; de Brum-Fernandes, A. Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts. J. Rheumatol. 2004, 31, 1598-1606.
54. Hackett, J.A.; Allard-Chamard, H.; Sarrazin, P.; de Fatima Lucena, M.; Gallant, M.A.; Fortier, I.; Nader, M.; Parent, J.L.; Bkaily, G.; de Brum-Fernandes, A.J. Prostaglandin production by human osteoclasts in culture. J. Rheumatol. 2006, 33, 1320-1328.
55. Yin, M.J.; Yamamoto, Y.; Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-beta. Nature 1998, 396, 77-80.
56. Jimi, E.; Aoki, K.; Saito, H.; D'Acquisto, F.; May, M.J.; Nakamura, I.; Sudo, T.; Kojima, T.; Okamoto, F.; Fukushima, H.; Okabe, K.; Ohya, K.; Ghosh, S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 2004, 10, 617-624.
57. Karakawa, A.; Fukawa, Y.; Okazaki, M.; Takahashi, K.; Sano, T.; Amano, H.; Yamamoto, M.; Yamada, S. Diclofenac sodium inhibits NFkappaB transcription in osteoclasts. J. Dent. Res. 2009, 88, 1042-107.
58. Feng, R.; Anderson, G.; Xiao, G.; Elliott, G.; Leoni, L.; Mapara, M.Y.; Roodman, G.D.; Lentzsch, S. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2007, 109, 2130-2138.
59. Kawashima, M.; Fujikawa, Y.; Itonaga, I.; Takita, C.; Tsumura, H. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod. Rheumatol. 2009, 19, 192-198.
60. Niki, Y.; Takaishi, H.; Takito, J.; Miyamoto, T.; Kosaki, N.; Matsumoto, H.; Toyama, Y.; Tada, N. Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction. J. Immunol. 2007, 179, 639-646.
61. Idris, A.I.; Del Soldato, P.; Ralston, S.H.; van't Hof, R.J. The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production. Bone 2004, 35, 636-643.
62. Idris, A.I.; Ralston, S.H.; van't Hof, R.J. The nitrosylatedflurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur. J. Pharmacol. 2009, 602, 215-222.
63. Kellinsalmi, M.; Parikka, V.; Risteli, J.; Hentunen, T.; Leskelä, H.V.; Lehtonen, S.; Selander, K.; Väänänen, K.; Lehenkari, P. Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favoursadipocyte formation in vitro. Eur. J. Pharmacol. 2007, 572, 102-110.
64. Goodman, S.B.; Ma, T.; Mitsunaga, L.; Miyanishi, K.; Genovese, M.C.; Smith, R.L. Temporal effects of a COX-2-selective NSAID on bone ingrowth. J. Biomed. Mater. Res. A. 2005, 72, 279-287.
65. Vuolteenaho, K.; Moilanen, T.; Moilanen, E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic. Clin. Pharmacol. Toxicol. 2008, 102, 10-14.
66. Nanke, Y.; Kotake, S.; Ninomiya, T.; Furuya, T.; Ozawa, H.; Kamatani, N. Geranylgeranylacetone inhibits formation and function of human osteoclasts and prevents bone loss in tail-suspended rats and ovariectomized rats. Calcif. Tissue. Int. 2005, 77, 376-385.
67. Nanke, Y.; Kawamoto, M.; Yago, T.; Chiba, J.; Yamanaka, H.; Kotake, S. Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblastlike synoviocytes from patients with rheumatoid arthritis. Mod. Rheumatol. 2009, 19, 379-383.